We’re less than two weeks away from another exciting translational phage conference! The Bacteriophage Therapy Summit will take place in Boston, Massachusetts March 25-27, 2019.
The meeting will focus on the discovery, translation and acceleration of phage research into targeted therapeutics. Register here and use code 12259PHD for 10% off.
The 2019 Evergreen Bacteriophage Meeting, taking place Aug 4-9, 2019 in Olympia, Washington, is now open for registration! If you work with phages, this iconic biennial (once per 2 years) meeting is not to be missed!
*COMING SOON: We’re helping Evergreen coordinate financial assistance for this conference. Interested? Email us at [email protected]!
Want to learn to analyze your (phage) genomes? The PATRIC/RAST teams will be offering a tutorial at Argonne National Laboratory in the suburbs of Chicago, IL from Apr 16-18, 2019. Email Lisa Hundley to sign up (hurry, workshop is free BUT limited to 40 participants).
Check out this exciting new preprint from the Banfield lab and colleagues. They sequenced DNA from diverse ecosystems and found HUNDREDS of huge phage genomes (up to 716 kbp). The phages they found encode lots of new things phages don’t typically have, such as new CRISPR-Cas systems, translation factors and ribosomal proteins!
Listen to Dr. Minmin Yen, co-founder & CEO of the new biotech startup PhagePro, discuss her company’s goals of preventing cholera with phages on the podcast “Important, Not Important”. An especially great listen for grad students & postdocs wondering about the transition from the bench to founding a biotech company! (61 min)
New feature! We’re adding commenting on Capsid & Tail articles. Visit this issue on our website (or any other issue) and scroll to the bottom to comment!
We are looking for a postdoc with strong quantitative skills as well as expertise in bioinformatics and computational genomics. The general aim of the project is to explore the diversity and specificity of interactions between bacteriophages and opportunistic bacterial pathogens in the family of Enterobacteriaceae, with primary emphasis on Klebsiella pneumoniae.
Have a question or request for the phage community? Post it here and reach > 300 phage enthusiasts spanning academia, industry, medicine, and beyond. Feel free to be creative about what you might ask! (e.g. collaborations, advice, seeking opportunities). Find the week’s new requests here in Capsid & Tail, or find a list of all active requests here.
Our group is looking to begin isolating and characterizing phages, first against fish pathogens, mainly at the molecular level. In the future, we will seek to exploit phages to control many animal pathogens. We are seeking help and support from phage experts during the learning curve process. I would also be very grateful if a phage lab could host me as a visiting scientist for a few days, to help me get acquainted with the process of phage manipulation. Please contact me at [email protected] to talk about this further.
Want to help #phagetherapy patients? Our collaboration between @IPATH & @TAMU_CPT needs environmental samples for #phagehunts! You can help by sending soil samples to @TAMU_CPT. Message Steffanie Strathdee (@chngin_the_wrld) on Twitter for details and may the #phage be with you! #AMR #superbugs #AntibioticResistance
Last week, we introduced a new paper describing use of a cystic fibrosis zebrafish model to test phage therapy outcomes. This week, we dive (pun intended) deeper into this paper to highlight this useful new animal model for the phage therapy community.
Zebrafish are becoming recognized as a promising animal model, especially for human biology studies, for a variety of reasons. Long story short, they’re cheaper than mice, they reproduce more rapidly, you can easily manipulate their genes, they’re transparent (so you can fluorescently label and then follow what happens to their cells, live, under the microscope), and mutation of many of their genes leads to similar disease phenotypes as we see in humans.
The authors of the paper we’re profiling here (Cafora et al. 2019) wanted to test whether phages could treat Pseudomonas aeruginosa infections in a cystic fibrosis (CF) zebrafish model. Zebrafish have a similar chloride ion pump (CFTR, cystic fibrosis transmembrane regulator) to humans, and it can be mutated in zebrafish, thus mimicking human CF.
CF patients have mutations in CFTR, so they have overly sticky mucus in their lungs, and are highly prone to infection throughout their lives. P. aeruginosa is a common culprit. CF patients end up receiving antibiotics extremely frequently, leading to antibiotic resistance, and so phage therapy may be a good option for CF patients.
No, they do not, which complicates use of zebrafish as a model for CF, since the disease primarily leads to lung infections. But zebrafish have mucins, which are the sugar-rich proteins that make up mucous, and zebrafish mucins are similar to human mucins. Also, CF affects other organs, not just lungs (e.g. the pancreas). Zebrafish do have a pancreas, and its function IS affected by the CFTR mutation, so the authors make the point that the fish is still a reasonably good model for studying CF.
They generated zebrafish embryos with CFTR mutations and infected them with a commonly studied P. aeruginosa strain called PAO1. They checked, and P. aeruginosa did indeed infect the CFTR mutant fish more effectively than wild type fish, just like P. aeruginosa infects people with CF more effectively than people without CF.
They used phages (and antibiotics, as a control, and also in combination with the phage treatment) to see if they could reduce the zebrafish mortality. They chose four phages, all able to infect the P. aeruginosa strain (which they GFP-labeled so they could follow its spread and growth in vivo), and used them together in a cocktail. They found that the phages did improve survival of the zebrafish, both in the wild type and CF embryos, and they concluded that combining phages with antibiotics led to the best results.
There hasn’t been a lot of research into the immune response to phages during phage therapy nor under natural conditions. This is likely to become a more active area of research, especially as phage therapy becomes more commonly administered.
Within days, zebrafish embryos have a fully developed innate immune system, and for their first 30 days, they ONLY have an innate immune system. So if you study them during this period, you don’t have to worry about the adaptive immune system, and can study the innate immune response in isolation. This is useful, because the innate immune system is the critical immune system at play when it comes to human lung infections.
Cafora et al. looked at the zebrafish immune response during their phage therapy experiments. They measured gene expression changes in two immune cytokines: IL-β and TNF-α, which are both indicators of inflammation.
P. aeruginosa + / - phage: In both wild type and CF fish, they saw that P. aeruginosa provoked an immune response, and that the phage cocktail reduced this immune response.
Naive fish: When neither the P. aeruginosa nor the phage was there, the CF fish appeared to exhibit a constitutive inflammatory state.
Phage alone: Phages administered alone (without P. aeruginosa) reduced the constitutive inflammatory state in the CF fish.
These authors validated a new model for testing phage therapy in a CF animal (and while they were at it, they also generated some interesting new leads on how their phages might interact with the innate immune system).
Other studies have previously evaluated phage therapy (against Vibrio anguillarum and Aeromonas hydrophila) within zebrafish, but this is the first to evaluate P. aeruginosa/phage pairs in zebrafish, and the first to do so in a CF-mimicking context in any animal model.
The zebrafish model is cheap, genetically tractable, and well-understood. It allows real time visualization of cells (including infecting bacterial strains!), and phages are able to infect cells while inside the fish, making it particularly useful for phage therapy experiments.
An added bonus with zebrafish is the ability to genetically manipulate it to mimic genetic diseases in humans, so we can test phage therapy in those contexts, as has been done here for CF.
At a time where we need to start collecting as much data as possible about how phages infect their hosts in vivo and how they impact immune responses (and not just in one or two phages, but in as many types as possible), using the zebrafish model could represent a great opportunity to start doing these experiments without spending a lot of money.
Here are some extra resources:
A great blog post from Elizabeth Burke at the NIH that explains why zebrafish make good animal models for human diseases.
A methods paper showing how to infect zebrafish embryos with Pseudomonas, and how to observe them under the microscope.
A paper showing successful phage treatment of Aeromonas hydrophila in zebrafish
A paper showing successful phage treatment of Vibrio anguillarum in zebrafish
The NIH Zebrafish Core:
A place to get help with your zebrafish experiments:
“The core’s goal is to help researchers of any expertise perform zebrafish experiments aimed at illuminating basic biology and human disease mechanisms.”
A comparison of the zebrafish genome and the human genome (sneak preview: around 70% of human genes have an obvious zebrafish counterpart)
Main source for this post:
Cafora, M., Deflorian, G., Forti, F., Ferrari, L., Binelli, G., Briani, F., … & Pistocchi, A. (2019). Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model. Scientific Reports, 9, 1-10.
For every issue of Capsid & Tail, we are committed to getting our facts straight, but we’re not experts in the information we’re bringing to you. If you feel that we’ve missed an important viewpoint, or if you have something to add, please reach out to us by emailing [email protected]. We’d love to hear from you, and we’d be happy to revisit topics we’ve covered (ideally with added information and viewpoints from community members like you!).
Lastly, please reach out if you’re interested in writing for us, or have suggestions for future issues!